LU 206907: A Prospective Trial of MRI-Based Brachytherapy for the Treatment of Carcinoma of the Cervix.

Eligibility:

- Cancer of the uterine cervix considered suitable for curative treatment with definitive adiotherapy with or without concurrent chemotherapy including MRI-based BT

- Positive biopsy showing squamous cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma of the uterine cervix

- Staging according to FIGO guidelines

- FIGO Stage IB1-IVA and/or Node Positive

- Para-aortic metastatic nodes below L1-L2 are allowed

- Cross-sectional imaging of the pelvis (MRI or CT) and PET-CT of the pelvis, retroperitoneal space, and abdomen at diagnosis is performed

- MRI with the applicator in pace at the time of (first) BT implant will be performed

- Patients enrolled to a cooperative group or other institutional trial

- Patient signed informed consent for collection of data
Exclusion Criteria:

1. Other histologies of cervical cancer
2. Metastatic disease beyond para-aortic region (L1-L2)
3. Previous pelvic or abdominal radiotherapy
4. Previous total or partial hysterectomy
5. Combination of preoperative radiotherapy with surgery
6. Patients receiving BT only
7. Patients receiving EBRT only
8. Contra indication to MRI
9. Contra indications to BT
10. Active infection of severe medical condition endangering treatment delivery
11. Pregnant, lactating or childbearing potential without adequate contraception